PT-141 is a research compound studied in cell-based assay formats for its selective MC3R and MC4R (class A GPCR) Gs/cAMP activation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems.

Receptor Pharmacology and Mechanism of Action

PT-141 acts via selective MC3R and MC4R (class A GPCR) Gs/cAMP activation. Competitive radioligand binding assays and functional cell-based assay formats provide quantitative endpoints for characterising receptor selectivity and downstream signalling cascade engagement.

Melanocortin Receptor Selectivity Profile

Cell-based functional assays demonstrate PT-141's preferential activation of MC3R and MC4R subtypes over MC1R and MC5R. Radioligand displacement studies using [125I]-NDP-MSH reveal distinct binding kinetics, with IC50 values indicating higher affinity for MC4R compared to other melanocortin receptor subtypes. Transfected cell models expressing individual receptor subtypes enable precise characterisation of selectivity ratios and binding kinetics.

Saturation binding experiments in recombinant cell systems demonstrate specific, saturable binding characteristics consistent with high-affinity receptor interactions. Scatchard analysis reveals single binding site populations with Kd values in the nanomolar range for MC4R-expressing cell models.

cAMP Signalling Pathway Activation

Functional assays measuring intracellular cAMP accumulation demonstrate PT-141's potent agonist activity at MC4R. Dose-response curves in transfected cell models show EC50 values consistent with high-potency receptor activation. Real-time cAMP measurements using FRET-based biosensors reveal rapid onset kinetics following receptor engagement.

Adenylyl cyclase activity assays in membrane preparations confirm Gs protein coupling and downstream effector activation. Time-course studies demonstrate sustained cAMP elevation over extended incubation periods, indicating stable receptor-ligand complex formation and persistent signalling pathway engagement.

Hypothalamic Cell Model Studies

Neuronal Cell Line Characterisation

Immortalised hypothalamic cell lines expressing endogenous MC4R provide physiologically relevant model systems for PT-141 pharmacological studies. GT1-7 and N38 hypothalamic cell models demonstrate measurable cAMP responses to PT-141 treatment, with concentration-dependent activation profiles.

Patch-clamp electrophysiology experiments in these neuronal models reveal PT-141-induced alterations in membrane potential and ion channel conductance. Whole-cell recordings demonstrate changes in voltage-gated calcium channel activity and potassium conductance following MC4R activation.

Primary Hypothalamic Culture Systems

Primary neuronal cultures derived from hypothalamic tissue provide native receptor expression patterns for PT-141 pharmacological characterisation. Calcium imaging studies using fluorescent indicators demonstrate PT-141-induced intracellular calcium mobilisation in MC4R-positive neurons.

Multi-electrode array recordings from hypothalamic slice preparations reveal PT-141-induced changes in spontaneous firing patterns and network activity. Extracellular field potential measurements demonstrate concentration-dependent modulation of neuronal excitability following peptide application.

Downstream Signalling Cascade Analysis

PKA Pathway Activation

cAMP-dependent protein kinase A (PKA) activity assays demonstrate PT-141-induced enzyme activation in MC4R-expressing cell models. Kinase substrate phosphorylation studies reveal time-dependent increases in CREB phosphorylation at Ser133, indicating transcriptional regulatory pathway engagement.

Western blot analysis of phospho-specific antibodies confirms PKA-mediated phosphorylation of downstream targets including CREB, ACC, and hormone-sensitive lipase in responsive cell models.

Transcriptional Response Elements

Reporter gene assays using CRE-luciferase constructs demonstrate PT-141-induced transcriptional activation in MC4R-expressing cells. Time-course studies reveal peak reporter activity 4-6 hours post-treatment, consistent with CREB-mediated gene expression programs.

qPCR analysis reveals PT-141-induced expression of immediate early genes including c-fos and POMC in hypothalamic cell models. Transcriptome profiling identifies broader gene expression changes associated with MC4R signalling pathway activation.

Enzyme Kinetics and Binding Dynamics

Kinetic binding experiments reveal PT-141's association and dissociation rates at MC4R. Surface plasmon resonance measurements demonstrate real-time binding kinetics with calculated kon and koff values for receptor interaction characterisation.

Competition binding assays with selective melanocortin antagonists confirm specific receptor-mediated interactions. Reversibility studies demonstrate competitive displacement by excess unlabelled ligand, supporting specific receptor binding mechanisms.

Research Summary

PT-141 demonstrates selective MC3R and MC4R agonist activity in cell-based assay systems, with preferential activation of hypothalamic signalling pathways. In vitro studies confirm high-affinity receptor binding, potent cAMP pathway activation, and downstream transcriptional responses in neuronal cell models. These pharmacological characteristics support continued investigation of melanocortin receptor signalling mechanisms in hypothalamic cell culture systems.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.